Document Detail


Antithrombotic therapy following bioprosthetic aortic valve replacement.
MedLine Citation:
PMID:  17267235     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The life expectancy of the general population is increasing. This has meant that more elderly patients are requiring aortic valve replacement (AVR). The choice of valve replacement and its durability are important. Bioprosthetic (tissue) heart valves were introduced into clinical use in the 1960s and were developed primarily to reduce the complications associated with thromboembolism (TE) and the need for lifelong oral anticoagulation, due to their low thrombogenicity compared to mechanical prostheses. This makes them suitable for use in elderly patients (aged>65 years) and in others where the risks of anticoagulation are higher or anticoagulation is contraindicated. There is thought to be a higher risk of TE for up to 90 days following bioprosthetic AVR. Guidelines for the management of patients with valvular heart disease published by the American College of Cardiology (ACC)/American Heart Association (AHA), the American College of Chest Physicians (ACCP) and the European Society of Cardiology (ESC) all recommend the use of an anticoagulation regimen for the first 3 months following bioprosthetic AVR. However, there is division of opinion and practice, despite these recommendations, and more recent studies have not supported the evidence for these guidelines. In this article, we review the literature on the use of anticoagulation in the first 90 days following bioprosthetic AVR.
Authors:
Justin Nowell; Emma Wilton; Hugh Markus; Marjan Jahangiri
Related Documents :
2980055 - The carpentier-edwards supra-annular porcine bioprosthesis: new generation low pressure...
1863145 - Aortic valve replacement with omniscience and omnicarbon valves.
15223405 - Risk of repeat mitral valve replacement for failed mitral valve prostheses.
8442985 - Six-year follow-up after heart valve replacement with the edwards duromedics bileaflet ...
19233855 - The influence of body mass index on mortality and bleeding among patients with or at hi...
25119055 - Radiological outcomes of pinless navigation in total knee arthroplasty: a randomized co...
Publication Detail:
Type:  Journal Article; Review     Date:  2007-01-30
Journal Detail:
Title:  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery     Volume:  31     ISSN:  1010-7940     ISO Abbreviation:  Eur J Cardiothorac Surg     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-19     Completed Date:  2007-06-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8804069     Medline TA:  Eur J Cardiothorac Surg     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  578-85     Citation Subset:  IM    
Affiliation:
Department of Cardiothoracic Surgery and Neurosciences, St George's Hospital, University of London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / adverse effects,  therapeutic use
Aortic Valve / surgery*
Bioprosthesis*
Fibrinolytic Agents / therapeutic use*
Heart Valve Prosthesis Implantation*
Hemorrhage / chemically induced
Humans
Postoperative Complications / prevention & control
Practice Guidelines as Topic
Risk Factors
Thromboembolism / prevention & control
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  'Turn-up' anastomotic technique for acute aortic dissection.
Next Document:  Right ventricular outflow tract reconstruction for pulmonary regurgitation after repair of tetralogy...